https://eureka.patsnap.com/resources/blog/rd-blog/subcutaneous-delivery-and-hyaluronidase-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Biologics Formulation
Subcutaneous Delivery and Hyaluronidase Patents: Mapping Who Owns the Claim Space
  • 29.5% of the field sits with five assignees. 2,567 of 8,714 records in scope belong to the top five, a concentration that narrows where a new entrant can file cleanly.
  • Filing has plateaued, not declined. 2021 to 2024 growth is +1% (439 to 444 records) — essentially flat, with 2025-26 figures still incomplete due to publication lag.
  • Medicinal preparations dominate the class mix. A61K appears on 79.2% of all 8,714 records, meaning most filings sit in formulation claims rather than device or delivery mechanics.
Get a prior-art report on your approach
8,714
Published Records
29%
Top-5 Share of All Records
+1%
Filing Growth 2021→2024
US
Leading Jurisdiction

Filing growth compares 2021 (439 records) with 2024 (444) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 8,714 records in scope (CR5), not by the ranked leaders only.

Published byPatsnap Research··7 min readSourced from Patsnap Eureka
Overview

What this landscape covers

This dataset tracks patent families addressing subcutaneous administration, hyaluronidase coformulation, and large volume injection, cross-referenced against the practical obstacles that make subcutaneous delivery hard: injection site reaction, bioavailability variability, dispersion in tissue, volume limits, pain perception, and device pairing. The scope spans 8,714 published records filed between 2015 and mid-2026.

The picture that emerges is a formulation-heavy field. Most activity clusters around medicinal preparation claims and peptide or protein chemistry, with a smaller but persistent layer of genetic engineering and heterocyclic compound filings. Concentration at the top is real but not extreme — the leader holds 843 records against a field of 8,714, leaving substantial room below the top ranks.

Filing volume and technology composition, 2015-2026
  1. 1IONIS PHARMACEUTICALS INC843
  2. 2REGENERON PHARMACEUTICALS INC522
  3. 3FIVE PRIME THERAPEUTICS INC448
  4. 4SANOFI BIOTECH SAS396
  5. 5SANOFI SA(FR)358
  6. 6GENENTECH INC351
  7. 7REGULUS THERAPEUTICS INC313
  8. 8ALKERMES PHARMA IRELAND LTD274
  9. 9F HOFFMANN LA ROCHE & CO AG177
  10. 10MEDIMMUNE LLC174
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Subcutaneous Delivery and Hyaluronidase covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP

Let an AI agent run this analysis on your own technology

Pick a task. Every answer cites the patents behind it.

10,000 free credits to start
The Numbers

Filing trends and technology composition

Two views of the same 8,714 records: how filing volume has moved year over year, and which IPC subclasses carry the claim weight.

Filing trend, 2017-2026

Filings ran from 454 in 2017 to a peak of 535 in 2019, then held roughly flat through the recent complete years — 439 in 2021 versus 444 in 2024, a +1% span. The 2025 and 2026 figures (49 for the partial latest year) understate true filing activity because publication typically lags filing by around 18 months.

Filing trend, 2017-20260150300450600454201720185352019202020212022202320242025492026Most recent year is partial — publication lag means later filings are not yet visible.

IPC subclass composition

A61K (medicinal preparations) covers 79.2% of the 8,714 records, far ahead of A61P (therapeutic activity, 48.8%) and C07K (peptides and proteins, 33.7%). Genetic engineering (C12N, 22.8%) and nucleic acid chemistry (C07H, 8.8%) form a smaller secondary layer. Because records carry multiple IPC codes, these shares sum to well over 100% and should be read against the full record count, not against each other.

IPC subclass compositionA61K · Medicinal preparations6,90279.2%A61P · Therapeutic activity of compou…4,25448.8%C07K · Peptides & proteins2,93533.7%C12N · Microorganisms & genetic engin…1,98722.8%C07H · Sugars & nucleic acids7688.8%C07D · Heterocyclic compounds6787.8%C12Q · Measuring & testing involving …3333.8%G01N · Material analysis & testing3243.7%Other8039.2%

Shares are the percentage of the 8,714 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.

Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Subcutaneous Delivery and Hyaluronidase covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.

Go deeper on Subcutaneous Delivery and Hyaluronidase with Eureka

This page is one run against one query. Ask Eureka your own question about subcutaneous delivery and hyaluronidase and every answer comes back with the patent numbers behind it.

Try Eureka
Key Patents

Representative and most-cited filings

Representative Filing
WO2009128918A82009-10-22

WO2009128918A8 — Combination therapy using a soluble hyaluronidase and a bisphosphonate

HALOZYME, INC.

Provided are combinations, compositions and kits containing a bisphosphonate composition and a soluble hyaluronidase composition formulated for subcutaneous administration. Such products can be used in methods of treating bisphosphonate-treatable diseases or conditions. Also provided are methods for subcutaneous administration of a bisphosphonate compound whereby the dosing regimen is substantially the same as for intravenous administration of the same dosage for treatment of the same bisphosphonate-treatable disease or condition.Filed by Halozyme, Inc., published 2009-10-22 — a foundational example of the hyaluronidase-coformulation approach that recurs across later filings in this dataset.

View full filing
Most-cited records in scope
#Publication no.Patent titleCitations
1WO2009006478A26-disubstituted bicyclic nucleic acid analogs1,261
2WO2008150729A2N-substituted-aminomethylene bridged bicyclic nucleic acid analogs1,255
3WO2008154401A2Carbocyclic bicyclic nucleic acid analogs1,249
4WO2008101157A15'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom976
5WO2011140249A2Antibodies that bind CSF1r811
6WO2013169264A1Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1r)690
7WO2014036357A1Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1r)687
8US8278425B2<i>N</i>-substituted-aminomethylene bridged bicyclic nucleic acid analogs640
9US8278283B26-disubstituted or unsaturated bicyclic nucleic acid analogs633
10US8278426B2Carbocyclic bicyclic nucleic acid analogs632

Citation counts favour older filings simply because they have had longer to accumulate citations inside this corpus — treat them as a signal of influence, not of current importance. Several of the highest-cited records relate to nucleic acid chemistry rather than subcutaneous delivery mechanics directly, reflecting how broadly the search terms pull in adjacent biologics chemistry.

Each row carries its publication number; clicking a row searches Eureka by that number.

Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Subcutaneous Delivery and Hyaluronidase covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself

Put your own technology through the same analysis


  
Where to run it
Fastest

Eureka on the web

When you want the answer in the next five minutes.

The agent works the prompt against patents and technical literature, citing every source.

Run your analysis now →
For builders

MCP server & REST API

When it has to run inside your own pipeline.

Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.

Browse MCP servers →
Insights

What the data means for a filing strategy

Three findings that shape where a new filing is likely to clear and where it will collide with dense prior art.

Concentration
29.5%
of 8,714 records held by top 5

The top is concentrated but not closed

Five assignees hold 2,567 of the 8,714 records in scope, and the leader alone accounts for 843. That leaves a long tail below tenth place (174 records) where filing density drops off quickly, suggesting formulation-specific niches are still open even as the broad hyaluronidase-coformulation approach is well covered near the top.

Ranking covers 100 companies, the full set the data endpoint returns.
Filing momentum
+1%
2021 to 2024 (439 to 444 records)

Flat, not falling

Complete-year filing counts moved from 439 in 2021 to 444 in 2024 — essentially flat. Figures for 2025 and 2026 are lower only because publication lags filing by roughly 18 months; they should not be read as a slowdown.

Peak filing year so far: 2019, at 535 records.
Class composition
79.2%
of records carry A61K

Formulation claims dominate over device claims

A61K medicinal preparation claims appear on the large majority of records, well ahead of genetic engineering (C12N, 22.8%) or analytical/testing classes (G01N, 3.7%). Device-pairing and dispersion-in-tissue language appears in the search terms but is thin in the IPC composition, pointing to a gap between the clinical problem and where claims are actually being written.

Shares sum above 100% because records carry multiple IPC codes.
Eureka AI Agent
Looking for what nobody has claimed yet?

Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to subcutaneous delivery and hyaluronidase, with the prior art for and against each one.

Find the white space →
Co-filing patterns
AssigneeCo-assigneeShared families
Regeneron PharmaceuticalsSanofi Biotech360
GenentechXenon Pharmaceuticals182
Five Prime TherapeuticsBristol-Myers Squibb145
GenentechF. Hoffmann-La Roche83
Regulus TherapeuticsBoard of Regents, The University of Texas System63
Ionis PharmaceuticalsSWAYZE ERIC E56
Ionis PharmaceuticalsBHANOT SANJAY38
Ionis PharmaceuticalsSETH PUNIT P37

Ten identified co-assignee pairs exist in this dataset, the strongest linking two large biologics filers at 360 shared records — evidence of sustained joint development programmes rather than one-off collaborations.

Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Subcutaneous Delivery and Hyaluronidase covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players

Who is active and where momentum is shifting

Recent-year momentum diverges sharply from historical volume: several of the largest historical filers show sharp year-over-year declines in the latest year, consistent with the publication lag rather than a genuine pullback.

Leader
843
records

Largest single filer by volume

The top-ranked assignee holds 843 of the 8,714 records in scope, well ahead of fifth place at 358 and tenth place at 174 — a steep drop-off that marks where the field opens up for newer entrants.

Ranking basis: 100 companies, the full ranked set.
Momentum
-88% YoY
latest-year change, leading assignee

Recent-year counts are still filling in

Several historically active assignees show latest-year filings at or near zero with YoY declines of -88% to -100%. This mirrors the roughly 18-month publication lag rather than an actual halt in R&D, so recent-year momentum figures should be read cautiously.

Momentum tracked for six named assignees in this dataset.
Co-filing
360 records
strongest co-assignee pair

Joint filings cluster around a few pairs

The strongest co-assignee relationship spans 360 shared records, with two further pairs at 182 and 145. These patterns typically reflect licensing or joint-development arrangements between a large-molecule originator and a formulation or hyaluronidase specialist.

10 co-assignee pairs identified in total.
🔍
Under-claimed sub-areas
Branches where filing density is thin relative to the clinical problem they address
Device-pairing sensors for injection depthDispersion-rate modelling in subcutaneous tissuePain-perception biomarkers tied to formulationVolume-limit extension via viscosity modifiersBioavailability variability testing protocols
Rank all filers by momentum →
Recent-year filing momentum by assignee
AssigneeRecent yearYoY
Regeneron Pharmaceuticals2-88%
Sanofi10%
Ionis Pharmaceuticals0-100%
Five Prime Therapeutics0-100%
Regulus Therapeutics0-100%
Sanofi Biotech0-100%
Genentech0-100%
Alkermes Pharma Ireland0-100%
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Subcutaneous Delivery and Hyaluronidase covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next

Where to take this analysis

The landscape points to specific next steps depending on whether the goal is freedom-to-operate, licensing, or new filing strategy.

Run a freedom-to-operate check on formulation claims

Given that 79.2% of records carry A61K medicinal preparation claims, any new subcutaneous formulation should be checked against this class specifically before drafting.

Explore claim scope in Eureka

Assess the under-claimed device-pairing branch

Device-pairing and dispersion-in-tissue language appears thin in the IPC composition relative to the clinical need described in the search scope, which may indicate open claim space.

Map white space in Eureka

Track momentum shifts among top filers

Latest-year declines across several leading assignees are consistent with publication lag; revisit this trend once 2025-26 data matures.

Monitor assignee activity in Eureka
Source: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Subcutaneous Delivery and Hyaluronidase covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ

Common questions on this landscape

Answers are grounded in the same dataset. Derived from a Patsnap search on Subcutaneous Delivery and Hyaluronidase covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP

Research Subcutaneous Delivery and Hyaluronidase in depth with Eureka

Go past this page: query the whole subcutaneous delivery and hyaluronidase corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.

Try Eureka

Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.

Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.

Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.

Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.

Help us improve

Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.